相关实验视频
Updated: Jun 22, 2025
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
145
使用临床和MRI测量对阿尔茨海默氏症神经病理的分类
Xiaowei Zhuang1,2,3, Dietmar Cordes1,4, Andrew R Bender1
1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Journal of Alzheimer's disease : JAD
|June 29, 2024
概括
机器学习模型使用可访问的生物标志物,如APOE基因型和MRI衍生的皮质厚度,准确地预测阿尔茨海默病 (AD) 神经病理学. 这些发现支持使用AD元区域来诊断现生个体的AD.
科学领域:
- 神经学 神经学
- 生物标志物 生物标志物
- 机器学习 机器学习
背景情况:
- 机器学习模型正在开发用于使用临床生物标志物的阿尔茨海默病 (AD) 诊断.
- 许多当前的模型缺乏对死后神经病理学数据的验证.
研究的目的:
- 训练机器学习模型使用临床可用的特征对尸检确认的严重AD神经病变进行分类.
- 为了对这些模型与体内粉样蛋白生物标志物进行验证.
主要方法:
- 利用国家阿尔茨海默氏症协调中心 (NACC) 关于阿尔茨海默氏症神经病理状态的死后数据.
- 包括人口统计,阿波利波蛋白E (APOE) 基因型和MRI衍生的皮质厚度 (AD元ROI).
- 训练后勤回归和随机森林模型,通过PET成像数据外部验证.
主要成果:
- 实现了84.03%的交叉验证准确度来分类严重的AD神经病理.
- 获得了70.14%的外部验证准确度,用于分类体内粉样蛋白阳性.
结论:
- 临床上可访问的特征 (APOE,皮质稀释) 可以分类死后的AD和体内粉样蛋白状况.
- 阿尔茨海默症的元ROI显示出在活着的个体中确定阿尔茨海默症神经病理状态的潜力.
更多相关视频
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.3K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.2K
相关概念视频
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
01:22Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178